

## \$100 billion of revenues up for grabs for drug manufacturers by 2020 as patents for key biologics expire

Écrit par GBI Research

Mardi, 14 Mars 2017 12:19 - Mis à jour Mardi, 14 Mars 2017 12:21

---



Although complexities inherent in biological drug manufacturing are creating barriers for further expansion,

Adam Bradbury and Risk Analysts at GBI Research challenge the dominance of the top players, as they state in their new report, [Biosimilars: Mandilwar](#).

Mandilwar explains: “In order to be successful in the biosimilars sector, companies must adopt the latest technologies and

A number of biologics are set to go off patent before 2020, which presents a huge opportunity for biosimilar manufacturers.

Pricing for biosimilars is usually 30–50% lower than the innovator product. These cost advantages will drive growth in the sector.

Bradbury concludes: “The biosimilar pipeline is robust, and most products are being developed for the top 10 biologics.